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Objectives: To assess the efficacy and safety profile of add-on cannabidiol (CBD) 
in patients with Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS) on 
clobazam and in the overall population of four randomized, controlled phase 3 trials.
Methods: Patients received plant-derived, highly purified CBD medicine (Epidiolex® 
in the USA; Epidyolex® in Europe; 100 mg/ml oral solution) at a dose of 10 or 20 mg/
kg/day, or placebo for 14 weeks. A subgroup analysis of patients on clobazam and 
meta-analysis by syndrome were conducted. The primary endpoint was percentage 
reduction in primary seizure type during the treatment period.
Results: 396 patients with LGS (49% on clobazam) and 318 patients with DS (64% on 
clobazam) were included. CBD treatment resulted in a reduction in primary seizure 
frequency vs placebo in the overall population (treatment ratio [95% confidence inter-
val]: LGS, 0.70 [0.62-0.80]; DS, 0.71 [0.60-0.83]) and in patients receiving clobazam 
(LGS, 0.56 [0.47-0.67]; DS, 0.63 [0.52-0.77]). The antiseizure efficacy of CBD was also 
demonstrated across other endpoints vs placebo (≥50% responder rate, total seizure 
frequency, number of seizure-free days, and Subject/Caregiver Global Impression of 
Change scores) in the overall populations and in patients receiving clobazam. There 
were higher incidences of somnolence and sedation in patients on CBD and clobazam. 
Most incidences of elevated transaminases occurred in patients on concomitant val-
proate and, to a lesser extent, clobazam.
Conclusions: Add-on CBD was effective in reducing seizures in the overall popula-
tions and in conjunction with clobazam. Somnolence and sedation occurred more fre-
quently in patients on CBD and clobazam.
K E Y W O R D S
cannabidiol, clobazam, epilepsies, myoclonic, epilepsy, lennox–gastaut syndrome, seizures
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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1  |  INTRODUC TION
Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS) are rare, 
severe epileptic encephalopathies with early childhood onset that 
highly impact mortality and quality of life.1-10 Prescribing appropri-
ate treatments for patients with LGS and DS can be complex, due to 
the prevalence of multiple seizure types and a high degree of treat-
ment resistance.4,11,12
LGS is characterized by drop seizures, which can result in falls 
and injuries, tonic seizures, and non-convulsive seizures.3,13 Patients 
with DS present with different seizure types, but most patients ex-
perience combinations of severe convulsive seizures, primarily gen-
eralized tonic–clonic, and clonic seizures, as well as focal, myoclonic, 
and atypical absence seizures.11,14 Seizure types change over time in 
both LGS and DS.5,11,15,16 Current guidelines for LGS recommend the 
use of valproate as first-line treatment, followed by add-on therapy 
including lamotrigine and rufinamide.12 The treatment recommenda-
tion for DS is valproate or clobazam as first-line therapy, with add-on 
stiripentol or topiramate if seizure control is suboptimal.11,14
Adequate seizure control remains a concern in both syndromes 
despite currently available treatment options;12,14 no single treat-
ment has been shown to be highly efficacious, and many patients 
receive multiple antiepileptic drugs (AEDs) without seizure con-
trol.14,17 There is a need for new treatment options for patients with 
LGS and DS, as better seizure control may lead to reduced mortality1 
and improvements in quality of life.11,18,19
Highly purified cannabidiol (CBD; Epidyolex® in Europe, GW 
Pharma [International] B.V., and Epidiolex® in the USA, Greenwich 
Biosciences, Inc.) is structurally distinct from other AEDs. While its 
mechanism of action has not been fully elucidated, it has multimodal 
effects including reducing neuronal hyperexcitability through tran-
sient receptor potential vanilloid 1 (TRPV1) channels, antagonizing 
G protein-coupled receptor 55 (GPR55) receptors, and inhibiting 
equilibrative nucleoside transporter 1 (ENT1) adenosine reuptake 
pumps.20,21 In four phase 3 randomized, controlled trials, add-on 
CBD demonstrated efficacy with an acceptable safety profile in 
patients with LGS (GWPCARE3/NCT02224560 and GWPCARE4/
NCT02224690) and DS (GWPCARE1B/NCT02091375 and 
GWPCARE2/NCT02224703).22-25 CBD is approved as Epidiolex® 
in the USA for the treatment of seizures associated with LGS, DS, 
or tuberous sclerosis complex in patients ≥1 years of age;26 CBD (as 
Epidyolex®) is approved in the EU for the adjunctive treatment of 
seizures associated with LGS or DS, in conjunction with clobazam, in 
patients ≥2 years of age.27
The overall population for the phase 3 trials comprised patients 
who were taking CBD as add-on therapy to a number of different 
AEDs, most commonly clobazam (LGS, 49%; DS, 64%) and valproate 
(LGS, 39%; DS, 66%). As a result of the current EU labeling, this ar-
ticle will focus on the efficacy and safety profile of CBD in patients 
on clobazam and the overall population. To further understand the 
magnitude of the treatment effect and safety profile of CBD as an 
add-on treatment in patients with LGS and DS, a post hoc meta-anal-
ysis by syndrome was also conducted.
2  |  METHODS
2.1  |  Patients
Key inclusion/exclusion criteria for the four pivotal trials of add-on 
CBD in LGS and DS have been published previously.22-25,28 In brief, 
for the two trials evaluating CBD in LGS, eligible patients were aged 
2-55 years, had documented failures on one or more AEDs, were 
currently taking one or more AEDs, and had at least two drop sei-
zures per week in the 4-week baseline period. For the two trials 
evaluating CBD in DS, eligible patients were aged 2-18 years, were 
taking one or more AEDs, were not completely controlled by cur-
rent AEDs, and had at least four convulsive seizures in the 4-week 
baseline period. In all trials, concomitant medications and interven-
tions needed to be stable for 4 weeks prior to screening and remain 
unchanged throughout the trial.
2.2  |  Trial design
All trials followed a similar design where eligible patients were 
randomized following a 4-week baseline period. Patients received 
a pharmaceutical formulation of highly purified CBD derived from 
Cannabis sativa L. plant (100 mg/ml oral solution; Epidyolex® in the 
EU; Epidiolex® in the USA) or placebo. In GWPCARE3 (LGS) and 
GWPCARE2 (DS), patients were randomized to receive 10 mg/
kg/day (CBD10) or 20 mg/kg/day (CBD20), or matched placebo. 
In GWPCARE4 (LGS) and GWPCARE1B (DS), patients were rand-
omized to receive CBD20 or matched placebo. In all trials, patients 
received double-blind treatment for 14 weeks, which included a 
2-week titration period (7 days [CBD10] or 11 days [CBD20] of dose 
escalation, starting daily dose of 2.5 mg/kg/day) and a maintenance 
period of 12 weeks of stable dosing. This was followed by a tapering 
period of 10 days and a 4-week safety follow-up period, or entry into 
an open-label extension trial (GWPCARE5, NCT02224573).
Protocols were approved by institutional review boards or inde-
pendent ethics committees at each trial site. Trials were performed 
in accordance with the Declaration of Helsinki and the Good Clinical 
Practice guidelines. All patients or their caregivers provided written 
informed consent before enrollment.
2.3  |  Outcome measures
Patients or caregivers recorded the number and type of seizures 
each day using an interactive voice response system. All seizure 
types or descriptions given were confirmed independently by an in-
dependent epilepsy study consortium using a standard protocol. The 
primary seizure type in the LGS trials was drop seizures, defined as 
tonic, tonic–clonic, or atonic seizures that could have led to a fall or 
injury. The primary seizure type in the DS trials was convulsive sei-
zures, defined as tonic, tonic–clonic, clonic, or atonic seizures. The 
safety profile was evaluated by recording adverse events.
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The primary efficacy endpoint for all trials was the change from 
baseline in primary seizure type frequency (over 28 days) during 
the entire treatment period (14 weeks). Key secondary endpoints 
were ≥50% responder rate, defined as the proportion of patients 
with ≥50% reduction in primary seizure type frequency during the 
treatment period, change from baseline in total seizure frequency 
over the treatment period, and Subject/Caregiver Global Impression 
of Change (S/CGIC) at the last visit. Other secondary endpoints in-
cluded ≥75% responder rate, defined as the proportion of patients 
with ≥75% reduction in primary seizure type frequency during the 
treatment period and the number of primary seizure type-free days.
2.4  |  Statistical analyses
The safety and intention-to-treat analysis sets included all rand-
omized patients who took at least one dose of CBD or placebo.
The similar trial designs across the pivotal trials allowed for pool-
ing of the outcome data. Efficacy data (primary endpoint and ≥50% 
responder rates) are presented for the pooled LGS and DS popu-
lations (CBD20 and all CBD [CBD10 and CBD20] groups), as well 
as by trial. The safety outcomes are presented for the pooled LGS 
and DS populations (CBD20 group); individual trial results for the 
CBD10 groups are also presented. The pooled DS safety population 
additionally included 24 patients from GWPCARE1A, a preceding 
dose-defining and pharmacokinetic trial, who had received CBD10 
(n = 8), CBD20 (n = 9), or matched placebo (n = 7).28 Additional ef-
ficacy data and safety data by trial are shown in the Supporting 
Information.
For by-trial analyses, the primary endpoint, change from baseline 
in primary seizure type frequency, was analyzed in GWPCARE1B, 
GWPCARE3, and GWPCARE4 using the Wilcoxon rank-sum test; 
the overall effect size was measured using the Hodges–Lehmann es-
timate of median difference. For GWPCARE2, the primary endpoint 
was analyzed using a mixed-effects model with repeated-measures 
implemented within the framework of general linear models using 
the negative binomial response distribution. The model included 
stratified age-group, time (baseline period or treatment period), 
treatment arm, and treatment arm-by-time interaction as fixed ef-
fects and patient as a random effect. The log-transformed number of 
days in which seizure data were reported was included as an offset.
In the meta-analysis, the primary endpoint was re-analyzed in 
GWPCARE1B, GWPCARE3, and GWPCARE4, using the same nega-
tive binomial regression (NBR) analysis used for GWPCARE2.
For the responder endpoint, ≥50% responder rates were ana-
lyzed by trial using the Cochran–Mantel–Haenszel test stratified by 
age-group. In the meta-analysis, the endpoint was re-analyzed using 
logistic regression, including stratified age-group and treatment arm 
as fixed effects.
Fixed-effects meta-analysis techniques were then used to com-
bine the log treatment ratios (from NBR analysis of the primary 
seizure count) and log odds ratios (from logistic regression analy-
sis ≥50% responder rates) from the individual trials. The interaction 
p-value tested the null hypothesis of homogeneity of the treatment 
effect across trials/dose comparisons.
Other secondary endpoints were analyzed by trial. The percent-
age change in total seizure frequency in GWPCARE1B, GWPCARE3, 
and GWPCARE4 was analyzed using the Wilcoxon rank-sum test; 
the overall effect size was measured using the Hodges–Lehmann 
estimate of median difference. GWPCARE2 was analyzed using the 
same NBR analysis stated above. Across all trials, S/CGIC was ana-
lyzed using ordinal logistic regression and the ≥75% responder rates 
analyzed using the Cochran–Mantel–Haenszel test. The change 
from baseline in the number of primary seizure type-free days was 
analyzed using analysis of covariance (ANCOVA).
To assess the effect of concomitant clobazam within each trial, 
the primary endpoint and total seizure endpoint were analyzed using 
the NBR described above including stratified age-group, time (base-
line period or treatment period), treatment arm, treatment arm-by-
time interaction, clobazam use, clobazam use-by-treatment arm 
interaction, and clobazam use-by-treatment arm-by-time interac-
tion as fixed effects and patient as a random effect. The responder 
endpoints and S/CGIC were analyzed separately using logistic re-
gression, and the change from baseline in the number of primary 
seizure type-free days was analyzed using ANCOVA. Each analysis 
included stratified age-group, treatment arm, clobazam use, and 
clobazam use-by-treatment arm-by-time interaction as fixed effects. 
The same fixed-effects meta-analysis techniques were then used to 
combine the treatment effects from the individual trials.
3  |  RESULTS
3.1  |  Patient demographics and baseline 
characteristics
Demographic and baseline characteristics are shown for the pooled 
LGS and DS populations in Table 1 and by trial in Table S1 and Table 
S2.
Overall, the pooled intention-to-treat populations consisted of 
396 patients with LGS and 318 patients with DS. In the LGS trials, 
161 and 235 patients received placebo and CBD, respectively, of 
whom 79 (49%) and 115 (49%) were on clobazam. In the DS trials, 
124 and 194 patients received placebo and CBD, respectively, of 
whom 79 (64%) and 125 (64%) were on clobazam.
Demographics and baseline characteristics for patients with LGS 
were generally similar between treatment arms, both in the overall 
population and in patients on clobazam. The mean age across both 
LGS trials was 15 years. Demographics and baseline characteristics 
were also similar between treatment arms for patients with DS. The 
mean age across DS trials was 9 years.
In the overall trial populations, the median number of concom-
itant AEDs was 3; the most common AEDs (>25% of patients) were 
clobazam, valproate, levetiracetam, lamotrigine, and rufinamide in 
patients with LGS and valproate, clobazam, stiripentol, levetirace-
tam, and topiramate in patients with DS.
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The median baseline drop seizure frequency (per 28 days) for pa-
tients with LGS was 79.0 for placebo, 86.9 for the CBD10 group, and 
78.1 for the CBD20 group. The median baseline convulsive seizure 
frequency (per 28 days) for patients with DS was 15.5 for placebo, 
13.5 for the CBD10 group, and 10.4 for the CBD20 group.
3.2  |  Efficacy outcome measures in patients 
with LGS
The re-analysis by trial and meta-analysis for overall and on-clobazam 
populations for drop seizure reduction and ≥50% responder rate are 
shown in Table 2. Original by-trial data for the LGS population are 
shown in Table S3.
In the meta-analysis of the overall population, CBD resulted in a 
greater reduction in drop seizures compared with placebo (treatment 
ratio 0.70 [95% confidence interval {CI}, 0.62-0.80], p < 0.0001). In 
the subgroups of patients on clobazam, there was also a marked re-
duction in drop seizure frequency versus placebo (0.56 [0.47-0.67], 
p < 0.0001). This effect was also reflected in the ≥50% responder 
odds ratios (overall population, 3.14 [2.04-4.81], p < 0.0001; patients 
on clobazam, 3.48 [1.96-6.17], p < 0.0001).
Other secondary endpoints by trial are shown in Table S4. 
Patients receiving either dose of CBD experienced a greater per-
centage reduction in total seizures compared with placebo, both in 
the overall population and in patients on clobazam. Similarly, a higher 
percentage of patients in the overall population and the subgroup of 
patients on clobazam reported an improvement in overall condition 
on the S/CGIC with either dose of CBD compared with placebo. CBD 
led to a greater rate of patients achieving ≥75% reduction in seizure 
frequency compared with placebo at CBD20; this effect appeared to 
be more pronounced in patients on clobazam treated with CBD20. 
The number of seizure-free days (per 28 days) was also greater in pa-
tients treated with either dose of CBD compared with placebo, both 
in the overall population and in patients on clobazam.
3.3  |  Efficacy outcome measures in patients 
with DS
The re-analysis by trial and meta-analysis for overall and on-
clobazam populations for convulsive seizure reduction and ≥50% 
responder rate are shown in Table 3. Original by-trial data for the DS 
population are shown in Table S5.
In the overall DS population, CBD resulted in a greater reduc-
tion in convulsive seizures (0.71 [0.60-0.83], p < 0.0001) and higher 
≥50% responder rates (2.34 [1.51-3.63], p = 0.0001) compared 
with placebo. Similarly, in subgroups of patients on clobazam, there 
was a reduction in convulsive seizure frequency (0.63 [0.52-0.77], 
p < 0.0001) and higher ≥50% responder rates (2.78 [1.62-4.77], 
p = 0.0002) in patients treated with CBD compared to those treated 
with placebo.
Other secondary endpoints by trial are shown in Table S6. 
Patients receiving either dose of CBD experienced a greater per-
centage reduction in total seizures compared with placebo, both 
in the overall population and in patients on clobazam. Similarly, a 
greater percentage of patients reported improvements in overall 
condition on the S/CGIC with both doses of CBD compared with 
TA B L E  2  Meta-analyses of reduction from baseline in primary seizures and ≥50% responder rates for LGS populations, overall and on 
clobazam (intention-to-treat population)
Trial
Treatment arm vs 
placebo
Overall On clobazam
Interaction 
p-value
Treatment/odds 
ratioa  (95% CI) p-value
Interaction 
p-value
Treatment/odds 
ratioa  (95% CI) p-value
Reduction in drop seizure frequency
GWPCARE3 CBD10 0.71 (0.56-0.89) 0.0032 0.9727 0.70 (0.51-0.98) 0.0355
CBD20 0.66 (0.53-0.83) 0.0005 0.0067 0.46 (0.33-0.64) <0.0001
GWPCARE4 CBD20 0.73 (0.59-0.90) 0.0036 0.0123 0.54 (0.40-0.73) <0.0001
Meta-analysis CBD10 + CBD20 0.8244 0.70 (0.62-0.80) <0.0001 0.1948 0.56 (0.47-0.67) <0.0001
CBD20 0.5363 0.70 (0.60-0.82) <0.0001 0.4734 0.51 (0.41-0.63) <0.0001
≥50% responder rate
GWPCARE3 CBD10 3.30 (1.48-7.35) 0.0035 0.5021 2.72 (0.96-7.67) 0.0584
CBD20 3.87 (1.76-8.53) 0.0008 0.7015 5.12 (1.81-14.54) 0.0021
GWPCARE4 CBD20 2.61 (1.35-5.06) 0.0044 0.6190 3.14 (1.26-7.81) 0.0140
Meta-analysis CBD10 + CBD20 0.7482 3.14 (2.04-4.81) <0.0001 0.6720 3.48 (1.96-6.17) <0.0001
CBD20 0.4545 3.07 (1.85-5.10) <0.0001 0.4879 3.88 (1.95-7.71) <0.0001
Note: Results are based on a fixed-effects meta-analysis. The interaction p-value tested the null hypothesis of homogeneity of the treatment effect 
across trials/dose comparisons.
Abbreviations: CBD10, cannabidiol 10 mg/kg/day; CBD20, cannabidiol 20 mg/kg/day; CI, confidence interval; LGS, Lennox–Gastaut syndrome.
aReductions in drop seizure frequency are displayed using treatment ratios; ≥50% responder rates are displayed using odds ratios.  
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placebo, in the overall population, and in the subgroup of patients on 
clobazam. CBD led to higher ≥75% responder rates compared with 
placebo in the overall population; this effect was more prominent 
in GWPCARE2 and generally comparable in the overall population 
and on-clobazam groups. Finally, the number of seizure-free days 
(per 28 days) was greater in patients treated with CBD20 compared 
with placebo in GWPCARE1, and in patients treated with CBD10 
in GWPCARE2, both in the overall population and in patients on 
clobazam.
3.4  |  Safety and tolerability
Adverse events for the pooled LGS and DS populations are summa-
rized by syndrome in Table 4.
The overall incidence of treatment-emergent adverse events 
(TEAEs) was greater in patients taking CBD compared with placebo; 
the incidence was similar between patients with LGS and DS. In the 
subgroup of patients on clobazam, there also appeared to be a sim-
ilar proportion of patients experiencing TEAEs compared with the 
overall population across the CBD dose groups.
Most adverse events were mild to moderate in severity. The 
most common TEAEs in any patient group were somnolence, de-
creased appetite, diarrhea, pyrexia, fatigue, and vomiting.
More patients treated with CBD compared with placebo re-
ported serious TEAEs and TEAEs leading to discontinuation, both 
in the overall population and in patients on clobazam. In the overall 
LGS and DS populations, there were a greater number of patients 
experiencing TEAEs leading to discontinuation in the CBD20 group 
compared with CBD10; however, the numbers of serious TEAEs 
were similar across the two CBD doses. In patients on clobazam, the 
incidence of serious TEAEs and TEAEs leading to discontinuation ap-
peared to be similar to the overall population.
Somnolence was the most commonly reported TEAE and was not 
considered dose-related. In patients treated with CBD, somnolence 
was reported in 52/235 (22%) of patients with LGS and 57/211 (27%) 
of patients with DS, of whom 35/52 (67%) and 48/57 (84%) were on 
clobazam. Comparatively, somnolence was reported in 12/161 (7%) 
and 16/131 (12%) of patients with LGS and DS treated with placebo, 
of whom 8/12 (67%) and 13/16 (81%) were on clobazam. Similarly, 
the majority of CBD patients in the LGS and DS populations who 
experienced sedation were also on clobazam (LGS, 11/12 patients, 
92%; DS, 6/7 patients, 86%). Other common TEAEs, such as de-
creased appetite and diarrhea, did not appear to be more common in 
patients on clobazam.
Increased aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) were the most common causes of treatment dis-
continuation in patients with LGS (AST, 6/235, 3%; ALT, 7/235, 3%), 
and DS (AST, 4/211, 2%; ALT 2/211, 1%) taking CBD. In patients 
treated with CBD, increased AST was reported as a TEAE in 11/235 
(5%) patients with LGS and 14/211 (7%) with DS, of whom 6/11 
(55%) and 13/14 (93%) were on clobazam. The majority of patients 
reporting increased AST as a TEAE were taking valproate (LGS, 
9/11 patients, 82%; DS, 14/14 patients, 100%). Similarly, increased 
ALT was reported as a TEAE in 15/235 (6%) patients with LGS and 
12/211 (6%) patients with DS, of whom 8/15 (53%) with LGS and 
TA B L E  3  Meta-analyses of reduction from baseline in primary seizures and ≥50% responder rates for DS populations, overall and on 
clobazam (intention-to-treat population)
Trial
Treatment arm vs 
placebo
Overall On clobazam
Interaction 
p-value
Treatment/odds 
ratioa  (95% CI) p-value
Interaction 
p-value
Treatment/odds 
ratioa  (95% CI) p-value
Reduction in convulsive seizure frequency
GWPCARE2 CBD10 0.70 (0.54-0.92) 0.0095 0.1691 0.63 (0.46-0.86) 0.0042
CBD20 0.74 (0.57-0.97) 0.0299 0.5702 0.69 (0.50-0.96) 0.0297
GWPCARE1 CBD20 0.67 (0.50-0.90) 0.0082 0.57 (0.40-0.83) 0.0032
Meta-analysis CBD10 + CBD20 0.8808 0.71 (0.60-0.83) <0.0001 0.7490 0.63 (0.52-0.77) <0.0001
CBD20 0.6170 0.71 (0.58-0.86) 0.0006 0.4490 0.64 (0.50-0.81) 0.0003
≥50% responder rate
GWPCARE2 CBD10 2.24 (1.06-4.73) 0.0346 0.9722 2.33 (0.96-5.68) 0.0623
CBD20 2.77 (1.32-5.82) 0.0073 0.8188 3.26 (1.28-8.26) 0.0130
GWPCARE1 CBD20 2.04 (0.93-4.51) 0.0768 0.2517 2.88 (1.06-7.84) 0.0382
Meta-analysis CBD10 + CBD20 0.8512 2.34 (1.51-3.63) 0.0001 0.8763 2.78 (1.62-4.77) 0.0002
CBD20 0.5837 2.40 (1.40-4.13) 0.0015 0.8612 3.08 (1.56-6.08) 0.0012
Note: Results are based on a fixed-effects meta-analysis. The interaction p-value tested the null hypothesis of homogeneity of the treatment effect 
across trials/dose comparisons.
Abbreviations: CBD10, cannabidiol 10 mg/kg/day; CBD20, cannabidiol 20 mg/kg/day; CI, confidence interval; DS, Dravet syndrome.
aReductions in convulsive seizure frequency are displayed using treatment ratios; ≥50% responder rates are displayed using odds ratios. 
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8/12 (67%) with DS were taking clobazam and 11/15 (73%) with LGS 
and 12/12 (100%) with DS were taking valproate.
4  |  DISCUSSION
As a result of the current EU indication for CBD, the primary aim 
of this manuscript was to assess the efficacy and safety profile of 
CBD in patients with LGS and DS on clobazam and in the overall 
population of four randomized controlled phase 3 trials. The over-
all trial population comprised patients who were taking CBD as an 
add-on to a number of different AEDs; the on-clobazam population 
across the trials accounted for 49% of patients with LGS and 64% 
of patients with DS. Pooled data for subgroups of patients with and 
without clobazam have been recently published.29-31
In a meta-analysis of the phase 3 trials, CBD was effective at 
reducing seizures in patients with LGS and DS in the overall pop-
ulation and in patients on clobazam. Compared with placebo, CBD 
resulted in a greater reduction in drop seizures in patients with LGS 
and convulsive seizures in patients with DS. The antiseizure effect of 
CBD was also seen in the ≥50% responder odds ratios in both syn-
dromes. Across the trials, there were a greater number of patients 
receiving CBD20 compared with CBD10; however, there seemed to 
be no consistent dose response between the two doses. The rec-
ommended maintenance CBD dose is therefore 10 mg/kg/day in 
patients with LGS or DS. As individual patients may show greater 
efficacy at higher doses, CBD may be titrated up to a maximum dose 
of 20 mg/kg/day.27
The number of seizure-free days is an important endpoint in pa-
tients with severe epilepsy, as it represents a reduction in overall 
seizure burden. Patients treated with CBD experienced more sei-
zure-free days than those in the placebo group, both in the overall 
population and in patients on clobazam. Importantly, the effects on 
seizure reduction are reflected by the improvements in patient-re-
ported outcomes such as the S/CGIC scores seen across all CBD 
groups compared with placebo.
The meta-analysis shows similar antiseizure efficacy for the 
overall population and for patients on clobazam. Some have previ-
ously questioned whether CBD has an antiseizure effect indepen-
dent of clobazam, or whether its efficacy is due to a bidirectional 
drug–drug interaction with clobazam leading to increased levels 
of active metabolites of both drugs.29-34 A recent trial in healthy 
volunteers found that active metabolites of both clobazam (N-
desmethylclobazam [N-CLB]) and CBD (7-hydroxy-cannabidiol 
[7-OH-CBD]) were increased when clobazam and CBD were co-ad-
ministered.34 The increase in N-CLB has also been demonstrated 
in other trials in patients with treatment-resistant epilepsy treated 
with clobazam and CBD.35,36 Increases in N-CLB levels are thought 
to be due to inhibition of cytochrome P450 (CYP) 2C19 by CBD.37,38 
As both N-CLB and 7-OH-CBD metabolites are active, an increase in 
either or both could contribute to treatment efficacy.
However, preclinical studies have indicated that CBD and 
clobazam also have independent antiseizure effects.39,40 Anderson 
et al studied the pharmacokinetic and pharmacodynamic interac-
tions between CBD and clobazam in the DS Scn1a+/− mouse model 
of epilepsy. Although subanticonvulsive doses of CBD increased 
plasma clobazam concentrations in the mice, they did not result in a 
greater anticonvulsive efficacy. A greater efficacy was only achieved 
when an anticonvulsive dose of CBD was administered in combina-
tion with clobazam.39 Similarly, using the maximal electroshock sei-
zure (MES) mouse model of generalized seizures, Rana et al showed 
that both CBD and clobazam caused brain exposure-dependent 
anticonvulsive effects compared with vehicle. The group demon-
strated synergism between CBD and clobazam in MES mice at all 
fixed-ratio combinations tested (3:1, 1:1, 1:3).40
The analysis of phase 3 trial data described here indicates that 
CBD showed antiseizure efficacy in an overall population that in-
cluded patients with LGS and DS who were and were not taking 
clobazam. In addition, an independent retrospective analysis of pa-
tients taking CBD for refractory epilepsy found that CBD was ef-
fective in reducing seizure frequency, with or without concomitant 
clobazam.41 The analysis also showed that changes in N-CLB and 
clobazam levels did not have a clinically significant correlation with 
changes in weekly seizure frequency.41
The importance of N-CLB level elevation for the antiseizure effi-
cacy of CBD was also questioned in two separate papers evaluating 
the efficacy of CBD in patients on stiripentol. Stiripentol is a potent 
CYP2C19 inhibitor; thus, the effect of CBD on N-CLB levels was less 
marked in patients on stiripentol. Nevertheless, these patients de-
rived efficacy from CBD.28,31
Importantly, the increase in exposure to active metabolites of 
CBD and clobazam may also lead to an increased risk of some adverse 
events. Some TEAEs, particularly somnolence and increased transam-
inases, appeared to occur more frequently in patients on clobazam; 
other common TEAEs, such as decreased appetite and diarrhea, did 
not seem to be reported more often in patients on clobazam.
Somnolence and sedation are common adverse events in pa-
tients on clobazam.42 The majority of patients who experienced 
somnolence in both the CBD and placebo groups were on clobazam. 
Other trials assessing CBD in patients with treatment-resistant ep-
ilepsy reported a high incidence of somnolence or similar adverse 
events, such as sedation, in patients on clobazam.28,35,36,41 Sedation 
was less commonly reported than somnolence in this meta-analysis; 
however, the majority of patients who reported sedation were also 
on clobazam. Consideration of a reduction in the dose of clobazam is 
recommended for patients who experience somnolence or sedation 
when clobazam is co-administered with CBD.27
The most common causes of treatment discontinuation in pa-
tients with LGS and DS were increased AST and ALT. Although many 
of the cases were in patients on clobazam, a greater proportion of 
patients with increased ALT and AST were taking concomitant val-
proate. It is recommended that if clinically significant increases of 
transaminases occur, CBD and/or concomitant valproate or cloba-
zam should be reduced or discontinued in all patients until trans-
aminase levels return to within normal limits.27 Valproate and other 
concomitant AEDs may also influence other aspects of the efficacy 
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and/or safety of CBD, but it is beyond the scope of this manuscript 
to evaluate this.
The subgroup analysis of patients on clobazam will aid clinicians 
in making informed decisions regarding the efficacy and safety of 
CBD when prescribed in conjunction with clobazam. However, there 
are several limitations to the analysis. First, the sample sizes of tri-
als feeding into the meta-analysis are limited, as the trials were not 
designed for analysis of the on-clobazam patient group. Second, 
patients were not randomized by clobazam status, which may con-
found interpretation of the results; patients in the on-clobazam 
group may have different characteristics, including altered seizure 
response. Similarly, the analysis does not take into consideration 
that some patients in the off-clobazam group may have previously 
tried and discontinued clobazam. Whether or not a patient was tak-
ing clobazam may have influenced the physician's decision regarding 
whether to enter them into the trial, thus introducing further bias.
It was not feasible to assess the impact of individual clobazam 
levels on efficacy and safety due to wide variation in clobazam for-
mulation, dose, and plasma levels, which were only assessed in a 
small number of patients before and during the treatment period. 
The dose of clobazam could be adjusted in patients experiencing ad-
verse events, which would also confound any analysis of the impact 
of clobazam dose on the efficacy and safety of CBD. Patients with 
LGS and DS commonly receive polypharmacy and take a variety of 
medications including AEDs, which were selected based on individual 
response and tolerability prior to participation in the trials. The anal-
yses presented here did not account for the influence of these con-
comitant medications on efficacy and safety of CBD, nor did they take 
into consideration the effect of pharmacogenetics and the impact of 
polymorphisms in genes coding for cytochrome P450 enzymes.
5  |  CONCLUSION
Add-on CBD was effective in reducing seizures in patients with LGS 
and DS, both in the overall trial populations and in conjunction with 
clobazam. The safety profile appeared similar between the overall 
population and those on clobazam, with the exception of certain 
adverse events. Somnolence and sedation were more frequently 
reported in those patients who had concomitant administration of 
CBD and clobazam.
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